Citations

Clear

4 citation(s) found for "Hong, Angela".

Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032
Testa, Stefano , Himes, Jonathon E. , Nouth, Serey C.L. , Pierpoint, Matthew , Binkley, Michael S., Hong, Angela , Brigman, Brian E. , Riedel, Richard F. , Kirsch, David G. , Moding, Everett J. , Moding, Everett J , Riedel, Richard F , Subramanian, Ajay , Ballman, Karla V. , Heise, Rachel S. , Nemat‐Gorgani, Neda , Sears, Timothy J. , Binkley, Michael S. , Kalbasi, Anusha K. , Corcoran, David L. , Rijn, Matt van de , Mowery, Yvonne Marie , Weinhold, Kent J.

Mayo Clinic

No container title available | November 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.11.01.25339299 | PMID 41282894 Get It

Abstract The addition of pembrolizumab to preoperative radiotherapy (RT) improved disease-free survival (DFS) for patients with stage III undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS) in the randomized SU2C-SARC032 trial. To precisely identify patients who benefit from pembrolizumab and RT, we performed comprehensive multi-omics profiling of pre- and post-treatment tumor and blood samples, including bulk RNA-seq, flow cytometry, and cytometry by time of flight. Additionally, we built a single-cell RNA-seq atlas spanning 65,786 cells from UPS and LPS to recover single-cell states in bulk tumor samples using digital cytometry. Two opposing tumor microenvironments (TMEs), immune-cold sarcoma ecotype 1 (SE1) and immune-hot sarcoma immune class E (SIC E), benefited from pembrolizumab. Pembrolizumab combined with RT caused an overall increase in activated CD8 + T cells, CD56 low NK cells, and T cell receptor diversity, while diminishing matrix-remodeling stromal cells and sarcoma cells. Our findings identify different mechanisms of response to pembrolizumab in localized, high-risk UPS/LPS and suggest that sarcoma TME signatures may identify patients most likely to benefit from adding pembrolizumab to preoperative RT.
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.
Hong, Angela , Schuetze, Scott M. , Wagner, Andrew J. , Attia, Steven , Bae, Susie , Tine, Brian Andrew Van, Freeman, Carolyn, Brigman, Brian E. , Kirsch, David G. , Mowery, Yvonne Marie , Ballman, Karla V. , Monga, Varun , Heise, Rachel S. , Choy, Edwin , Burgess, Melissa , Pryor, David I. , Tinoco, Gabriel , Chmielowski, Bartosz , Rijn, Matt van de , Riedel, Richard F.

Mayo Clinic

Journal of Clinical Oncology | June 13, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11504-11504

10.1200/jco.2024.42.16_suppl.11504 Get It

11504 Background: Surgery & radiation therapy (RT) yield high local control rates for soft tissue sarcoma (STS) of the extremity and limb girdle. However, patients (pts) with high-grade stage III STS are at significant risk for developing metastasis. Median survival for pts with metastatic STS is < 2 years. SARC028 (NCT02301039) evaluated the efficacy of pembrolizumab (pembro) for metastatic STS, showing 20% and 8.7% response rates in undifferentiated pleomorphic sarcoma (UPS) and pleomorphic/dedifferentiated liposarcoma (LPS), respectively. We hypothesized that neoadjuvant pembro with concurrent RT followed by surgery and adjuvant pembro for stage III UPS, including myxofibrosarcoma, or LPS would stimulate an anti-tumor immune response to eliminate micrometastatic disease & improve disease-free survival (DFS). SU2C-SARC032 (NCT03092323) is a multi-institutional, international, randomized phase 2 trial evaluating the safety and efficacy of adding pembro to standard of care (SOC) RT & surgery for pts with stage III UPS or LPS. Methods: Pts aged > 12 yo with stage III (FNCLCC grade 2 or 3) UPS or LPS of the extremity and limb girdle were enrolled. Pts were randomized (1:1, stratified by grade) to neoadjuvant RT (50 Gy/25 fx) then surgery (SOC arm) or neoadjuvant pembro and RT then surgery & adjuvant pembro (EXP arm). Pembro was given 200 mg IV Q3 wk for 3 doses (before, during & after RT) & up to 14 adjuvant cycles. The primary endpoint was 2-yr DFS. Secondary endpoints included local recurrence-free survival (LRFS), distant disease-free survival (DDFS), & overall survival (OS). Target enrollment of 126 evaluable patients (max 144 total) provided 80% power (1-sided α = 0.05) to distinguish between a null hypothesis of 50% 2-yr DFS rate & alternative hypothesis of 75% 2-yr DFS rate by log-rank test, with initial analysis at 45 DFS events. Cox models were stratified by grade; primary analysis was a one-sided stratified log-rank test. Results: Between July 2017-November 2023, 143 patients were enrolled, predominantly with UPS (85%) & grade 3 (64%) histology. Median follow-up for alive patients is 24.1 mo. DFS in the EXP arm is significantly higher than the SOC arm (p = 0.023; HR 0.57, 90% CI: 0.35, 0.91). Estimated 2-yr DFS is 53% (90% CI: 43, 66%) for SOC vs 70% (90% CI: 61, 81%) for EXP arm. Currently, there is no statistically significant difference in LRFS (HR 0.55, 95% CI: 0.21, 1.42), DDFS (HR 0.57, 95% CI: 0.32, 1.01), or OS (HR 0.39, 95% CI: 0.14, 1.12). Pts with grade 3 sarcomas had improved DFS with pembro (HR 0.47, 95% CI: 0.25, 0.89), but no difference in DFS was observed in grade 2 tumors (HR 1.21, 95% CI: 0.35, 4.18). The proportion of patients with grade 3+ adverse events was significantly higher in EXP (52%) vs SOC arm (26%) (p = 0.002). Conclusions: Theaddition of neoadjuvant & adjuvant pembro to RT and surgery significantly improves DFS for pts with stage III UPS and LPS of the extremity and limb girdle. Clinical trial information: NCT03092323 .
Clinical Characteristics and Longitudinal Outcomes in Heterogeneous Emphysema in SPIROMICS
Hong, Angela , Newell, John D. , Valipour, Arschang , Ortega, Victor E. , Cooper, C.B., Hansel, Nadia N. , Paine, Robert , Woodruff, P., Hong, A., Eddy, Rachel L. , Goldin, Jonathan , Hoffman, Eric A. , Abtin, Fereidoun G. , Criner, Gerard J. , Reinhardt, Joseph M. , Barr, R. Graham , Ohar, Jill , Curtis, Jeffrey L. , Cooper, C.B. , Drummond, Michael , Han, MeiLan King , Labaki, Wassim W. , Martínez, Fernando J. , Wells, J. Michael , Tashkin, Donald P. , Barjaktarević, Igor

Mayo Clinic

D13. DETERMINANTS OF DISEASE PROGRESSION AND DECLINE IN COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6905-A6905

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6905 Get It

Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers
Carter, Simon , Gutman, Talia , Logeman, Charlotte , Cattran, D C, Lightstone, Liz , Bagga, Arvind , Barbour, Sean J. , Barratt, Jonathan , Boletis, John , Caster, Dawn J. , Floege, Jürgen , Hogan, Jonathan J., Lafayette, Richard , Malvar, Ana , Scholes‐Robertson, Nicole , Trimarchi, Hernán, Zhang, Hong , Ažukaitis, Karolis , Viecelli, Andrea K. , Dunn, Louese, Harris, David C.H. , Johnson, David W. , Laboi, Paul, Ryan, Jessica , Ruiz, Lorena , Wang, Angela Yee‐Moon , Lee, Achilles Hoi Kan, Fung, Samuel , Tong, M.K.H. , Teixeira‐Pinto, Armando , Alexander, Stephen I. , Craig, Jonathan C. , Investigators, on behalf of the SONG-GD, Floege, Jürgen , Kitching, A Richard , Johnson, David W , Wang, Angela Yee-Moon , Wilkie, Martin , Carter, Simon A , Barratt, Jonathan , Scholes-Robertson, Nicole , Coppo, Rosanna , Fervenza, Fernando C. , Hladunewich, Michelle , Hogan, Jonathan J. , Kitching, A. Richard , Malvar, Ana , Radhakrishnan, Jai , Rovin, Brad H. , Trimarchi, Hernán , Cho, Yeoungjee , Kerr, Peter G. , Shen, Jenny I. , Tong, Allison , Investigators, on behalf of the SONG-GD

Mayo Clinic

Clinical Journal of the American Society of Nephrology | April 30, 2020 | Volume: 15 | Issue: 5 | Pages: 673-684

10.2215/cjn.13101019 | PMID 32354728 Get It

Background and objectives Shared decision making in patients with glomerular disease remains challenging because outcomes important to patients remain largely unknown. We aimed to identify and prioritize outcomes important to patients and caregivers and to describe reasons for their choices. Design, setting, participants, & measurements We purposively sampled adult patients with glomerular disease and their caregivers from Australia, Hong Kong, the United Kingdom, and the United States. Participants identified, discussed, and ranked outcomes in focus groups using the nominal group technique; a relative importance score (between zero and one) was calculated. Qualitative data were analyzed thematically. Results Across 16 focus groups, 134 participants (range, 19–85 years old; 51% women), including 101 patients and 33 caregivers, identified 58 outcomes. The ten highest-ranked outcomes were kidney function (importance score of 0.42), mortality (0.29), need for dialysis or transplant (0.22), life participation (0.18), fatigue (0.17), anxiety (0.13), family impact (0.12), infection and immunity (0.12), ability to work (0.11), and BP (0.11). Three themes explained the reasons for these rankings: constraining day-to-day experience, impaired agency and control over health, and threats to future health and family. Conclusions Patients with glomerular disease and their caregivers highly prioritize kidney health and survival, but they also prioritize life participation, fatigue, anxiety, and family impact.